NCT05886491: An ongoing trial by Takeda
This trial is ongoing. It must report results 8 months, 1 week from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05886491 |
|---|---|
| Title | A Phase 1/2a, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety and Efficacy of GDX012 in Patients With Relapsed or Refractory Acute Myeloid Leukemia |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 11, 2023 |
| Completion date | Aug. 20, 2025 |
| Required reporting date | Aug. 20, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |